NOVELTY - Preparing (M) a microfluidized lysate preparation, comprising microfluidizing a slurry of at least one Leishmania parasite (LP) through a chamber and disrupting LP with a sudden release of pressure, is new.    USE - (I) is useful for a skin test antigen assay for detecting whether a subject had been exposed to a Leishmania parasite or was afflicted with Leishmaniasis, by administering (I) to the subject, and observing any immunogenic response to (I), where the immunogenic response indicates that the subject had been exposed to LP or was afflicted with Leishmaniasis. An induration of about 5 mm or greater observed indicates that the subject had been exposed to LP or was afflicted with Leishmaniasis. (I) is also useful for determining whether a subject has been exposed to a given LP, by administering a panel of antigenic compositions comprising (I) prepared from several LPs, to the subject, and detecting a presence of an immunogenic reaction that is characteristic to exposure to the given LP. (I) is also useful for immunizing a subject against Leishmaniasis. (I) is useful for determining post infection of cutaneous leishmaniasis, mucocutaneous leishmaniasis and post-kalaazar dermal leishmaniasis in a subject, for epidemiologically diagnosing cutaneous leishmaniasis, mucocutaneous leishmaniasis and post-kalaazar dermal leishmaniasis in a subject, and for determining the pattern of present and past leishmaniasis in a subject, by administering (I) to the subject, and observing any immunogenic response to (I) (claimed). (I) is used to elicit induration that is consistent with delayed type hypersensitivity in an individual previously infected with or exposed to LP. (I) is useful as immunogens to raise anti-Leishmanial antibodies. Ab is useful for isolating Leishmanial antigens, and to diagnostically monitor protein levels in a tissue as part of a clinical testing procedure e.g. to determine the efficacy of a given treatment regimen.    ADVANTAGE - (I) is made under current good manufacturing practice, and is thus standardized. (I) is produced consistently.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:    (1) a microfluidized lysate preparation (I), obtained by M1;    (2) a kit comprising (I), and directions for determining whether a subject has been exposed to LP or was afflicted with Leishmaniasis;    (3) an antibody (Ab) raised against (I);    (4) a vaccine comprising (I); and    (5) a pharmaceutical composition (PC) comprising (I) and a pharmaceutically acceptable stabilizer.    DESCRIPTION OF DRAWING(S) - The figure shows a flow diagram showing the process of making a Leishmaniasis microfluidized lysate.